Psithera Inc. completed a spinout from Roivant, rebranding and securing $47.5 million in Series A financing to advance small‑molecule programs against immune and inflammatory targets. The company appointed Eric Shaff as president and CEO and signaled plans to deploy its Quaisar computational platform and chemistry assets toward a diversified pipeline. The financing and leadership moves position Psithera to accelerate preclinical work and candidate selection. The spinout reflects continued repackaging of Roivant‑originated assets into standalone biotech ventures supported by venture capital and strategic investors.